A high level of serum uric acid prior to implantation of bare-metal coronary stents predicts stent restenosis, according to research published in the The American Journal of Cardiology (2014;113:197-202).
Osman Turak, MD, of the Turkiye Yuksek Ihtisas Training and Research Hospital in Ankara, Turkey, and colleagues analyzed data from 708 consecutive patients (mean age, 60.3; 71% men) with stable or unstable angina pectoris who received bare-metal coronary stents. The authors sought to assess the association between serum uric acid (SUA) level and in-stent restenosis (ISR).
Among patients grouped by tertiles according to preprocedural SUA level, stent restenosis occurred in 23% in the lowest tertile, 34% in the middle tertile, and 46% in the highest tertile. Independent predictors of ISR identified by multiple logistic regression analysis included diabetes mellitus, smoking, high-density lipoprotein cholesterol level, stent length, C-reactive protein level, and preprocedural SUA level. Further analysis showed that SUA level greater than 5.5 mg/dL had 75% sensitivity and 71% specificity in predicting ISR.
“In conclusion, higher preprocedural SUA is a powerful and independent predictor of bare-metal stent restenosis in patients with stable and unstable angina pectoris,” the authors wrote.